Novo Nordisk Once-Weekly Insulin Hits Primary Goals In In Two Phase 3 Trials
- Novo Nordisk A/S announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes.
- In ONWARDS 3 study, after 26 weeks of treatment, hemoglobin A1c, a measure of blood sugar, had fallen 1.57% from a baseline of 8.5% in the insulin icodec cohort, compared to a 1.36% reduction in the control group.
- Related: Novo Nordisk's Once-Weekly Insulin Icodec Shows Favorable Reduction In HbA1c In Type 2 Diabetes.
- Novo saw no statistically significant difference in severe or clinically significant hypoglycemia, although the rate was numerically higher in the insulin icodec group.
- The firm said the drug appeared safe and well tolerated.
- In ONWARDS 4 study, after 26 weeks, hemoglobin A1c had fallen 1.16% from a baseline of 8.3% in the insulin icodec cohort, compared to a 1.18% reduction in the control group.
- Novo now has data from five of the six phase 3 ONWARDS program trials. Top-line results from the remaining study, ONWARDS 5, are due by the end of the year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.